文献速递细菌感染、耐药与抗菌药物

纳米粒共载环丙沙星和美罗培南增强对MDR-hvKP临床分离株的协同活性

Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

本研究将环丙沙星与美罗培南共载入纳米聚合物基质,评估其对10株MDR-hvKP临床分离株的协同活性及在大鼠脓毒症模型中的疗效。纳米药物组合对7/10株显示协同活性,游离组合仅2株协同;纳米组合显著提高生存率并降低细菌负荷(P ≤ 0.0001)。

要点

  • 纳米环丙沙星/美罗培南对7/10株MDR-hvKP协同,游离组合仅2株协同。
  • 纳米药物MIC较游离药物降低2-4倍(环丙沙星)和4-16倍(美罗培南)。
  • 大鼠脓毒症模型中纳米组合显著改善生存并降低细菌负荷(P ≤ 0.0001)。

核心结论

  • 双抗生素载纳米粒对MDR-hvKP感染具有创新治疗潜力,纳米技术可能帮助克服耐药病原体。

研究设计与样本

  • 实验研究,纳入10株临床肺炎克雷伯菌分离株,通过毒力基因p-rmpA和iucA确认hvKP。
  • 采用棋盘法和时间杀菌试验评估游离与纳米环丙沙星/美罗培南的协同活性。
  • 在大鼠脓毒症模型中评估生存率和细菌负荷。

主要发现

  • hvKP菌株对纳米药物的MIC显著低于游离药物:纳米环丙沙星MIC 2–32 mg/L,纳米美罗培南MIC 0.125–64 mg/L。
  • 纳米环丙沙星/美罗培南组合对7/10株hvKP显示协同,3株相加;游离组合仅2株协同、2株相加、6株无关。
  • 时间杀菌试验中单药治疗不能抑制细菌生长,纳米组合在1×MIC时具有杀菌活性。
  • 与游离药物组合相比,纳米环丙沙星/美罗培南显著提高生存率并降低细菌负荷(P ≤ 0.0001)。

关键数值与推荐

  • 纳米环丙沙星MIC范围2–32 mg/L,较游离药物降低2-4倍。
  • 纳米美罗培南MIC范围0.125–64 mg/L,较游离药物降低4-16倍。
  • 纳米组合对7/10株协同、3株相加;游离组合对2株协同、2株相加、6株无关。
  • 纳米组合在1×MIC时显示杀菌活性,单药治疗不能抑制生长。
  • 大鼠模型中纳米组合较游离组合显著改善生存和降低细菌负荷(P ≤ 0.0001)。

临床怎么用

  • 纳米共载环丙沙星和美罗培南可能增强对MDR-hvKP的协同杀菌作用,但尚需临床研究验证。

局限性

  • 仅测试10株临床分离株,样本量有限。
  • 研究为体外和动物模型,尚未进行人体临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the growing concern over MDR hypervirulent Klebsiella pneumoniae (MDR-hvKP), effective treatments remain limited. AIM: This study explores the potential of co-loading ciprofloxacin and meropenem into a nano-polymeric matrix to enhance their synergistic activity against MDR-hvKP and improve treatment outcomes in a hvKP-infected rat model. METHODS: Ten clinical K. pneumoniae isolates were tested for virulence genes (p-rmpA, iucA) to confirm the presence of hvKP. The synergistic activity of free-ciprofloxacin/meropenem and nanosized ciprofloxacin/meropenem was evaluated using checkerboard and time-kill assays. Survival rates and bacterial burden were assessed in a rat sepsis model after receiving either nano- or free-ciprofloxacin/meropenem. RESULTS: HvKP strains exhibited significantly lower MICs for nanosized drugs compared with free drugs. MICs of nano-ciprofloxacin ranged from 2 to 32 mg/L, and nano-meropenem from 0.125 to 64 mg/L, reflecting 2-4- and 4-16-fold reductions compared with free drugs. Nano- ciprofloxacin/meropenem combination displayed synergistic activity against 7 out of 10 hvKP strains and additive activity against three strains. By contrast, free-ciprofloxacin/meropenem showed synergy in only two strains, additive effects in two strains and indifferent activity in six strains. Time-kill assays demonstrated that monotherapies failed to inhibit bacterial growth, while nanosized combination exhibited bactericidal activity at 1×MIC. Nano-ciprofloxacin/meropenem significantly improved survival and reduced bacterial load compared with free drugs combination (P ≤ 0.0001). CONCLUSION: Dual antibiotic-loaded nanoparticles represent an innovative therapeutic approach against hvKP infections and highlight nanotechnology's potential in overcoming MDR pathogens for future clinical application.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mostafa R, Mohammed S, Ahmed AS, et al. Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates. J Antimicrob Chemother. 2026. PMID: 41334656. doi:10.1093/jac/dkaf422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。